Built on Strong Partnerships and Strategic Alliances

An office conference room with glass walls all around

Non-dilutive financing and partnerships have been critical to our vision of developing therapeutics for areas of unmet need.

Spero Therapeutics is actively pursuing collaborations with non-commercial organizations and pharmaceutical partners for scientific expertise and funding support.

A closeup of two people sitting on a bench in the park

As a growing clinical stage biopharmaceutical company, we have alliances with or received funding support from the following:

  • Biomedical Advanced Research and Development Authority (BARDA), part of the Health and Human Services Office of the Administration for Strategic Preparedness & Response;
  • U.S. Defense Threat Reduction Agency (DTRA);
  • U.S. National Institute of Allergy and Infectious Diseases (NIAID);
  • U.S. Department of Defense (DoD);
  • Bill & Melinda Gates Medical Research Institute (Gates MRI);
  • Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator (CARB-X);
  • Everest Medicines
  • Pfizer
  • GSK
  • Vertex Pharmaceuticals

Since its founding, Spero has built strategic partnerships to advance its multi-asset, clinical-stage pipeline, raising over $65 million in committed non-dilutive funding since inception, with the potential to receive up to a total of $130 million in such funding, including potential milestone opportunities and full awards.

We intend to continue collaborating with government agencies, non-profit foundations and pharmaceutical partners to support the development of our product candidates.
‍
Spero Therapeutics welcomes inquiries regarding potential opportunities for collaboration across discovery, development and commercialization.

For more information about partnership opportunities, contact us.

Investor Relationships

Stock information, SEC filings, corporate governance, IR resources and more.

Explore Resources

Careers

Collaborative. Exciting. Challenging. Stimulating. Committed. Spero Therapeutics was founded in 2013.

Learn More

Sign up to receive news and announcements.

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.